Merck & Co., Inc.





Market Closed - Nyse 04:00:01 2024-03-01 pm EST 5-day change 1st Jan Change
127 USD -0.15% Intraday chart for Merck & Co., Inc. -1.92% +16.46%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
India's Serum boosts supply of cervical cancer shots ahead of government's mass drive RE
US judge upholds Medicare drug price negotiation program RE
Merck's Bridion faces generic threat from drugmaker Hikma RE
Merck Says EMA Committee Endorses Keytruda Combination for Resectable Lung Cancer MT
Merck's Lung Cancer Therapy Receives Positive Opinion for EU Approval MT
Merck: positive CHMP opinion for Keytruda in NSCLC CF
Merck Gets CHMP Backing for Keytruda in Certain Non-Small Cell Lung Cancer DJ
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence CI
Weight-loss drugs could boost US GDP by 1% in coming years, Goldman says RE
Merck's Keytruda Gets FDA's Priority Review for Endometrial Carcinoma MT
Merck: priority review in endometrial cancer. CF
Merck Gets Speedy FDA Review for New Keytruda Uterine Cancer Indication DJ
FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma CI
Merck & Co. Insider Sold Shares Worth $29,538,998, According to a Recent SEC Filing MT
Merck & Co. Insider Sold Shares Worth $4,805,521, According to a Recent SEC Filing MT
Soros Fund Management Llc Dissolves Share Stake In General Motors, Apple, Maplebear; Takes Share Stake In Merck RE
Putin says Russia is close to creating cancer vaccines RE
Merck & Co. Insider Sold Shares Worth $1,845,083, According to a Recent SEC Filing MT
Merck Gets Health Canada's Approval of Keytruda Combination to Treat Gastric Cancer MT
Merck: new approval for Keytruda in Canada CF
Health Canada Approves Keytruda® in Combination with Trastuzumab and Chemotherapy, as A First-Line Treatment for Patients with Locally Advanced Her2-Positive Gastric or Gastric or Gastroesophageal Junction Adenocarcinoma CI
Adagene Gets China Clearance to Assess Colorectal Cancer Treatment Combination MT
US Senate Democrats grill pharma CEOs on drug prices RE
Merck Canada Collaborates With Vector Institute on AI in Healthcare MT
Merck & Co. Insider Sold Shares Worth $2,411,111, According to a Recent SEC Filing MT
Chart Merck & Co., Inc.
More charts
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
127 USD
Average target price
134.1 USD
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock Merck & Co., Inc. - Nyse
  4. News Merck & Co., Inc.
  5. Merck Says FDA Grants Priority Review to Application for Keytruda Plus Padcev for Urothelial Cancer Treatment
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.